Connor, Clark & Lunn Investment Management Ltd. Y M Abs Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 94,225 shares of YMAB stock, worth $897,964. This represents 0.01% of its overall portfolio holdings.
Number of Shares
94,225
Previous 176,055
46.48%
Holding current value
$897,964
Previous $2.13 Million
41.82%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding YMAB
# of Institutions
107Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$38.9 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$28 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$20.9 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$19.4 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$17.4 Million0.15% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $417M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...